Oral acetazolamide for Sodium valproate related weight gain in Bipolar disorder
Not Applicable
Completed
- Conditions
- Health Condition 1: F317- Bipolar disorder, currently in remission
- Registration Number
- CTRI/2019/05/019075
- Lead Sponsor
- Dr Mathews Joseph Panicker
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 13
Inclusion Criteria
Out patients or in patients diagnosed as Bipolar Affective Mood Disorder using MINI PLUS and only on Sodium Valproate.
-Both males and females
-18 â?? 60 years of age
-Without any co-morbid psychiatric illness other than nicotine use.
Exclusion Criteria
-Persons on Acetazolamide for any medical reasons.
-No known medical conditions in which acetazolamide is contraindicated like hyperchloremic acidosis, hypokalemia, hyponatremia, adrenal insufficiency, impaired kidney function, hypersensitivity to acetazolamide or other sulphonamides, liver diseases.
-Pregnancy, lactation
-Sub normal intelligence
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the effect of Acetazolamide on weight when combined with Sodium Valproate in patients diagnosed with Bipolar Affective DisorderTimepoint: 8 weeks
- Secondary Outcome Measures
Name Time Method ILTimepoint: NI